Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles?

References

• Defining governanceOttawaInstitute on Governance2003 Available from: https://iog.ca/docs/2003_August_policybrief15.pdfAccessed October 15, 2017
   Google Scholar
• Governance for sustainable human development: a UNDP policy documentNew YorkUnited Nations Development Program1997 Available from: http://www.pogar.org/publications/other/undp/governance/undppolicydoc97-e.pdfAccessed October 15, 2017
   Google Scholar
• Stewardship/governance of health systems in the WHO European RegionEUR/RC58/9. 28CopenhagenWHO Regional Office for Europe2008 Available from: http://www.euro.who.int/__data/assets/pdf_file/0016/70180/RC58_edoc09.pdfAccessed October 15, 2017
   Google Scholar
• Guidelines for the Economic Evaluation of Health Technologies: CanadaOttawaCanadian Agency for Drugs and Technologies in Health2017 Available from: https://www.cadth.ca/guidelines-economic-evaluation-health-technologies-canada-4th-editionAccessed October 15, 2017
   Google Scholar
• AnisAHGuhDWangXHA dog’s breakfast: prescription drug coverage varies widely across CanadaMed Care200139431532611329519
   PubMed Web of Science ®Google Scholar
• WestRBordenEKColletJPRawsonNSBTonksRS“Cost- effectiveness” estimates result in flawed decision-making in listing drugs for reimbursementCan J Public Health200293642142512448863
   PubMed Web of Science ®Google Scholar
• DemersVMeloMJackeviciusCComparison of provincial prescription drug plans and the impact on patients’ annual drug expendituresCMAJ2008178440540918268266
   PubMed Web of Science ®Google Scholar
• LeLorierJBellABougherDJCoxJLTurpieAGGDrug reimbursement policies in Canada: need for improved access to critical therapiesAnn Pharmacother200842686987318477735
   PubMed Web of Science ®Google Scholar
• SkinnerBJWaiting for reimbursement of new medicines in Canada: it’s time for a rethinkPharmacoeconomics200826862963218620457
   PubMed Web of Science ®Google Scholar
• RawsonNSBDrug Safety: Problems, Pitfalls and Solutions in Identifying and Evaluating RiskVictoria, BCFriesenPress2016
   Google Scholar
• Board of DirectorsOttawaCanadian Agency for Drugs and Technologies in Health2017 Available from: https://www.cadth.ca/about-cadth/who-we-are/board-of-directorsAccessed October 15, 2017
   Google Scholar
• What we doOttawaCanadian Agency for Drugs and Technologies in Health2017 Available from: https://www.cadth.ca/about-cadth/what-we-doAccessed October 15, 2017
   Google Scholar
• CADTH pan-Canadian Oncology Drug ReviewOttawaCanadian Agency for Drugs and Technologies in Health2017 Available from: https://www.cadth.ca/pcodrAccessed October 15, 2017
   Google Scholar
• CADTH Common Drug Review (CDR)OttawaCanadian Agency for Drugs and Technologies in Health2017 Available from: https://www.cadth.ca/about-cadth/what-we-do/products-services/cdrAccessed October 15, 2017
   Google Scholar
• The pCODR Expert Review Committee (pERC)OttawaCanadian Agency for Drugs and Technologies in Health2017 Available from: https://www.cadth.ca/collaboration-and-outreach/advisory-bodies/pcodr-expert-review-committee-percAccessed October 15, 2017
   Google Scholar
• Canadian Drug Expert Committee (CDEC)OttawaCanadian Agency for Drugs and Technologies in Health2017 Available from: https://www.cadth.ca/collaboration-and-outreach/advisory-bodies/canadian-drug-expert-committee-cdecAccessed October 15, 2017
   Google Scholar
• RawsonNSBHas pCODR improved access to oncology drugs? Timeliness and provincial acceptance of pan-Canadian Oncology Drug Review recommendationsVancouverFraser Institute20146 Available from: https://www.fraserinstitute.org/sites/default/files/has-pCODR-improved-access-to-oncology-drugs-rev.pdfAccessed October 15, 2017
   Google Scholar
• GriffithsEAVadlamudiNKCADTH’s $50,000 cost-effectiveness threshold: fact or fiction?Waltham, MAParexel International Corporation2016 Available from: https://www.ispor.org/research_pdfs/54/pdffiles/PHP278.pdfAccessed October 15, 2017
   Google Scholar
• RocchiAMillerEHopkinsRBGoereeRCommon Drug Review recommendations: an evidence base for expectations?Pharmacoeconomics201230322924622283689
   PubMed Web of Science ®Google Scholar
• RawsonNSBAre the cost-effectiveness rules used by public drug plans denying coverage to Canadians with rare disorders?Canadian Health PolicyTorontoCanadian Health Policy Institute2015 Available from: http://www.canadianhealthpolicy.com/products/are-cost-effectiveness-rules-in-public-drug-plans-denying-coverage-to-canadians-with-rare-disorders-.htmlAccessed October 15, 2017
   Google Scholar
• GriffithsEAHendrichJKStoddartSDRWalshSCMAcceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness thresholdClinicoecon Outcomes Res2015746347626366099
   PubMedGoogle Scholar
• TranKRawsonNSBSkinnerBJHTA decisions and access to mental health treatments in Canada’s public drug plansCanadian Health PolicyTorontoCanadian Health Policy Institute2017 Available from: http://www.canadianhealthpolicy.com/products/hta-decisions-and-access-to-mental-health-treatments-in-canada---s-public-drug-plans.htmlAccessed October 15, 2017
   Google Scholar
• GrosseSDAssessing cost-effectiveness in healthcare: history of the $50,000 per QALY thresholdExpert Rev Pharmacoecon Outcomes Res20088216517820528406
   PubMedGoogle Scholar
• RawsonNSBHealth technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and costOrphanet J Rare Dis20171215928330479
   PubMed Web of Science ®Google Scholar
• TsoiBO’ReillyDMasucciLDrummondMGoereeRHarmonization of HTA-based reimbursement and regulatory approval activities: a qualitative studyJ Popul Ther Clin Pharmacol2015221e788925715384
   PubMedGoogle Scholar
• Who we areOttawaCanadian Agency for Drugs and Technologies in Health2017 Available from: https://www.cadth.ca/about-cadth/who-we-areAccessed October 15, 2017
   Google Scholar
• The Common Drug Review-myths versus factsOttawaCanadian Agency for Drugs and Technologies in Health2017 Available from: https://www.cadth.ca/media/cdr/cdr-pdf/cdr_myths_facts_e.pdfAccessed October 15, 2017
   Google Scholar
• O’RourkeBStanding Committee on HealthOttawaParliament of Canada2016 Available from: http://www.parl.gc.ca/HousePublications/Publication.aspx?DocId=8185563&Language=E&Mode=1Accessed October 15, 2017
   Google Scholar
• RawsonNSBIncluding off-label drug indications in HTA jeopardizes patient health and discourages innovationCanadian Health PolicyTorontoCanadian Health Policy Institute2016 Available from: http://www.canadianhealthpolicy.com/products/including-off-label-drug-indications-in-hta-jeopardizes-patient-health-and-discourages-innovation.htmlAccessed October 15, 2017
   Google Scholar
• Updates to the therapeutic review frameworkOttawaCanadian Agency for Drugs and Technologies in Health2015 Available from: https://www.cadth.ca/updates-therapeutic-review-frameworkAccessed October 15, 2017
   Google Scholar
• Anti-vascular endothelial growth factor drugs for the treatment of retinal conditions-recommendations reportOttawaCanadian Agency for Drugs and Technologies in Health2016 Available from: https://www.cadth.ca/sites/default/files/pdf/TR0009_Anti-VEGFs_Recs_Report.pdfAccessed October 15, 2017
   Google Scholar
• About the PMPRBOttawaGovernment of Canada2017 Available from: http://www.pmprb-cepmb.gc.ca/homeAccessed October 15, 2017
   Google Scholar
• ZhangRMartinDNaylorCDRegulator or regulatory shield? The case for reforming Canada’s Patented Medicine Prices Review BoardCMAJ201718914E5151628396326
   PubMed Web of Science ®Google Scholar
• Protecting Canadians from excessive drug prices: consulting on proposed amendments to the patented medicines regulationsOttawaGovernment of Canada2017 Available from: https://www.canada.ca/en/health-canada/programs/consultation-regulations-patented-medicine/document.htmlAccessed October 15, 2017
   Google Scholar
• The pan-Canadian Pharmaceutical AllianceOttawaCouncil of the Federation Secretariat2013 Available from: http://www.pmprov-incesterritoires.ca/en/initiatives/358-pan-canadian-pricing-allianceAccessed October 15, 2017
   Google Scholar
• Questions for discussionTorontoPan-Canadian Pharmaceutical Alliance2016 Available from: http://www.pmprb-cepmb.gc.ca/CMFiles/Consultations/Rethinking_the_Guidelines_2016/Submission_PCPA_Oct_2016.pdfAccessed October 15, 2017
   Google Scholar
• MorganSGMartinDGagnonMAMintzesBDawJRLexchinJThe future of drug coverage in CanadaVancouverUniversity of British Columbia2015 http://pharmacare2020.ca/assets/pdf/The_Future_of_Drug_Coverage_in_Canada.pdfAccessed: October 15, 2017
   Google Scholar
• MorganSGLiWYauBPersaudNEstimating effects of adding universal public coverage of an essential medicines list to existing public drug plans in CanadaCMAJ20171898E295E30228246223
   PubMed Web of Science ®Google Scholar
• RawsonNSBFewer treatment options for patients if Canada adopts New Zealand’s prescription drug policiesCanadian Health PolicyTorontoCanadian Health Policy Institute2016 Available from: http://www.canadianhealthpolicy.com/products/fewer-treatment-options-for-patients-if-canada-adopts-new-zealand--s-prescription-drug-policies-.htmlAccessed October 15, 2017
   Google Scholar
• CDR Update – Issue 119OttawaCanadian Agency for Drugs and Technologies in Health2016 Available from: https://www.cadth.ca/cdr-update-issue-119Accessed October 15, 2017
   Google Scholar
• RawsonNSBPresentation at Healthy Canada Conference 2017: access to affordable medicinesOttawaConference Board of Canada2017 Available from: http://www.conferenceboard.ca/Libraries/CONF_PRES_PUBLIC/17-0064_p8_rawson.sflbAccessed October 15, 2017
   Google Scholar
• Improving health and social care through evidence-based guidanceLondonNational Institute for Health and Care Excellence2017 Available from: https://www.nice.org.ukAccessed October 15, 2017
   Google Scholar
• DPAC Formulary Working GroupOttawaCanadian Agency for Drugs and Technologies in Health2017 Available from: https://www.cadth.ca/collaboration-and-outreach/advisory-bodies/dpac-formulary-working-groupAccessed October 15, 2017
   Google Scholar
• pCODR Provincial Advisory GroupOttawaCanadian Agency for Drugs and Technologies in Health2017 Available from: https://www.cadth.ca/collaboration-and-outreach/advisory-bodies/pcodr-provincial-advisory-groupAccessed October 15, 2017
   Google Scholar
• BoardLondon: National Institute for Health and Care Excellence2017 Available from: https://www.nice.org.uk/about/who-we-are/boardAccessed October 15, 2017
   Google Scholar
• NICE charterLondonNational Institute for Health and Care Excellence2017 Available from: https://www.nice.org.uk/Media/Default/About/Who-we-are/NICE_Charter.pdfAccessed October 15, 2017
   Google Scholar
• Social value judgements: principles for the development of NICE guidance2nd edLondonNational Institute for Health and Care Excellence2017 Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/Research-and-development/Social-Value-Judgements-principles-for-the-development-of-NICE-guidance.pdfAccessed October 15, 2017
   Google Scholar
• What are the societal values that need to be considered when making decisions about trade-offs between equity and efficiency?NICE Citizens Council Meeting ReportMay 8–9, 2014LondonNational Institute for Health and Care Excellence2017 Available from: https://www.nice.org.uk/Media/Default/Get-involved/Citizens-Council/Reports/cc-report17-equity-efficiency.pdfAccessed October 15, 2017
   Google Scholar
• DrummondMSorensonCNasty or nice? A perspective on the use of health technology assessment in the United KingdomValue Health200912Suppl 2S8S1319523188
   PubMed Web of Science ®Google Scholar
• FischerKEHeisserTStargardtTHealth benefit assessment of pharmaceuticals: an international comparison of decisions from Germany, England, Scotland and AustraliaHealth Policy2016120101115112227628196
   PubMed Web of Science ®Google Scholar
• RafteryJPowellJHealth technology assessment in the UKLancet201338299001278128524120204
   PubMed Web of Science ®Google Scholar
• Guide to the processes of technology appraisalLondonNational Institute for Health and Care Excellence2014 Available from: https://www.nice.org.uk/process/pmg19/chapter/the-appraisal-processAccessed October 15, 2017
   Google Scholar
• Bevacizumab (Avastin) for eye conditions: report of findings from a workshop held at NICE on 13 July 2010LondonNational Institute for Health and Care Excellence2010 Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/Proposed-appraisals-no-wave/bevacizumab-exploratory-work-workshop-findings.pdfAccessed: October 15, 2017
   Google Scholar
• Eculizumab for treating atypical hemolytic uremic syndrome: highly specialized technologies guidanceLondonNational Institute for Health and Care Excellence2015 Available from: https://www.nice.org.uk/guidance/hst1/resources/eculizumab-for-treating-atypical-haemolytic-uraemic-syndrome-pdf-1394895848389Accessed October 15, 2017
   Google Scholar
• CDEC final recommendation, eculizumab (Soliris–Alexion Pharmaceuticals Inc.), new indication: atypical hemolytic uremic syndromeOttawaCanadian Agency for Drugs and Technologies in Health2013 Available from: https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Soliris-aHUS_July-23-13.pdfAccessed October 15, 2017
   Google Scholar
• CDR request for advice reportOttawaCanadian Agency for Drugs and Technologies in Health2015 Available from: https://www.cadth.ca/sites/default/files/cdr/advice/SF0416_Soliris_aHUS_RfA_Report.pdfAccessed October 15, 2017
   Google Scholar
• Framework agreement between the Department of Health and the National Institute for Health and Care Excellence 2014LondonNational Institute for Health and Care Excellence2014 Available from: https://www.nice.org.uk/Media/Default/about/who-we-are/NICE-and-Dept-of-Health-Framework-Agreement-March-2014.pdfAccessed October 15, 2017
   Google Scholar
• WaleJScottAMHofmannBGarnerSLowESansomLWhy patients should be involved in health technology assessmentInt J Technol Assess Health Care20173311428528585
   PubMed Web of Science ®Google Scholar
• Health technology assessment in Canada: improving the system and ensuring the patient voice is heardEtobicoke, ONBest Medicines Coalition2014 Available from: https://bestmedicinescoalition.org/wp-content/uploads/2017/03/HealthTechnologyAssessment.pdfAccessed October 15, 2017
   Google Scholar
• Public involvement programme annual report 2015LondonNational Institute for Health and Care Excellence2015 Available from: https://www.nice.org.uk/Media/Default/GetInvolved/Public%20Involvement/public_involvement_annual_report_2015.pdfAccessed October 15, 2017
   Google Scholar
• HusereauDDempsterWBlanchardAChambersJEvolution of drug reimbursement in Canada: the pan-Canadian Pharmaceutical Alliance for new drugsValue Health201417888889425498784
   PubMed Web of Science ®Google Scholar
• RawsonNSBPan-Canadian Pharmaceutical Alliance: another hurdle for Canadian patients to access new drugs?Canadian Health PolicyTorontoCanadian Health Policy Institute2016 Available from: http://www.canadianhealthpolicy.com/products/pan-canadian-pharmaceutical-alliance--another-hurdle-for-canadian-patients-to-access-new-drugs-.htmlAccessed October 15, 2017
   Google Scholar
• GrégoireJPMacNeilPSkiltonKInter-provincial variation in government drug formulariesCan J Public Health200192430731211962119
   PubMed Web of Science ®Google Scholar
• WestRBordenEKColletJPRawsonNSBTonksRSNeed for an improved submission process for listing drugs for reimbursement in Canadian provincesCan J Clin Pharmacol200310420721014712327
   PubMedGoogle Scholar
• MenonDStafinskiTStuartGAccess to drugs for cancerCan J Public Health200596645445816350873
   PubMed Web of Science ®Google Scholar
• UngarWJWitkosMPublic drug plan coverage for children across Canada: a portrait of too many coloursHealthc Policy20051110012219308106
   PubMedGoogle Scholar
• GambleJMWeirDLJohnsonJAEurichDTAnalysis of drug coverage before and after the implementation of the Common Drug ReviewCMAJ201118317E1259126622025648
   PubMed Web of Science ®Google Scholar
• GillSSGuptaNBellCMRochonPAAustinPCLaupacisAThe timing of drug funding announcements relative to elections: a case study involving dementia medicationsPLoS One201382e5692123460820
   PubMed Web of Science ®Google Scholar
• KerrAToddCUlyateKHebbornAA comparison of international health technology assessment systems – does the perfect system exist? Dee Why, NSW: Roche Products (Australia)2014 Available from: https://www.ispor.org/research_pdfs/48/pdffiles/PHP221.pdfAccessed October 15, 2017
   Google Scholar
• NP view: new bill falls short of Liberals’ promises for increased transparencyNational PostTorontoNational Post2017929 Available from: http://nationalpost.com/opinion/np-view-trudeau-promised-to-make-government-more-transparent-their-new-bill-does-the-oppositeAccessed October 15, 2017
   Google Scholar
• Right to knowGatineau, QuebecOffice of the Information Commissioner of Canada2014 Available from: http://www.oic-ci.gc.ca/rtk-dai-eng/historique-history.aspxAccessed October 15, 2017
   Google Scholar
• Openness. Transparency. Fairness. Making government work for CanadiansOttawaLiberal Party of Canada2017 Available from: https://www.liberal.ca/openness-and-transparencyAccessed October 15, 2017
   Google Scholar
• TrudeauJOpen and accountable governmentOttawaHer Majesty the Queen in Right of Canada2015 Available from: http://pm.gc.ca/sites/pm/files/docs/OAG_2015_English.pdfAccessed October 15, 2017
   Google Scholar
• StarrKJustin Trudeau hints at national child-care plan tied to incomeCBC/Radio-CanadaOttawaCBC/Radio-Canada201559 Available from: http://www.cbc.ca/news/politics/justin-trudeau-hints-at-national-child-care-plan-tied-to-income-1.3065235Accessed October 15, 2017
   Google Scholar